Urofollitropin|
| Trade names | Bravelle, Fertinex |
|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
|---|
Routes of administration | Subcutaneous, intramuscular |
|---|
| ATC code | |
|---|
|
| Legal status |
|
|---|
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| IUPHAR/BPS | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEMBL | |
|---|
| ECHA InfoCard | 100.212.030 |
|---|
|
| Formula | C975H1513N267O304S26 |
|---|
| Molar mass | 22672.95 g·mol−1 |
|---|
N Y (what is this?) (verify) |
Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified[1] to remove various proteins and other substances. FSH is important in the development of follicles (eggs) produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility.[2] It is also used with in vitro fertilization methods. The dosage is adjusted to each individual's response.[2]
The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma. It is not for use during pregnancy, as there is evidence for birth defects under follitropin treatment.[2]
Bravelle sold in the United States from March 2014 through October 2015 is subject to a recall and refund by its maker, Ferring Pharmaceuticals, because certain batches of the medicine had a lower strength than stated.[3]
References
External links
- Bravelle Archived 2010-12-27 at the Wayback Machine, by Ferring Pharmaceuticals, Switzerland
- Fostimon Archived 2010-11-15 at the Wayback Machine by Institut Biochemique SA, Switzerland
Merck & Co., Inc. |
|---|
| Corporate directors |
- Richard Clark
- Johnnetta Cole
- William Harrison
- William Kelley
- Rochelle Lazarus
- Thomas Shenk
- Anne Tatlock
- Samuel Thier
- Wendell Weeks
- Peter Wendell
|
|---|
| Subsidiaries |
- Acceleron Pharma
- Cubist Pharmaceuticals
- H. K. Mulford Company
- Schering-Plough
- Viralytics
|
|---|
| Products |
|
|---|
| Facilities |
- Merck Headquarters Building
|
|---|
| Publications |
- Merck Manual of Diagnosis and Therapy
- The Merck Manuals
- Index
- Manual
- Veterinary
- Geriatrics
|
|---|
|
|---|
GnRH modulators (incl. analogues) | | Agonists | |
|---|
| Antagonists |
- Non-peptide: Elagolix
- Linzagolix†
- Relugolix (+estradiol/norethisterone acetate)
|
|---|
|
|---|
| Gonadotropins | |
|---|
Others (indirect) | | Progonadotropins |
- Sex steroid antagonists (via disinhibition of the HPG axis): Antiandrogens (e.g., flutamide, bicalutamide, enzalutamide)
- Antiestrogens/SERMsTooltip Selective estrogen receptor modulators (e.g., tamoxifen, clomifene, enclomifene)
- Aromatase inhibitors (e.g., anastrozole)
- GnRH agonists (e.g., GnRHTooltip gonadotropin-releasing hormone)
|
|---|
| Antigonadotropins |
- Sex steroid agonists (via negative feedback on the HPG axis): Androgens/anabolic steroids (e.g., testosterone, nandrolone esters, oxandrolone)
- D2 receptor antagonists (prolactin releasers) (incl., domperidone, metoclopramide, risperidone, haloperidol, chlorpromazine, sulpiride)
- Estrogens (incl., bifluranol, estradiol, estradiol esters, ethinylestradiol, diethylstilbestrol, paroxypropione)
- Progestogens (incl. progestins, e.g., chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, gestonorone caproate, medroxyprogesterone acetate, megestrol acetate)
|
|---|
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- GnRH and gonadotropin receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- Progestogens and antiprogestogens
|
|
|---|
| GnRHTooltip Gonadotropin-releasing hormone receptor |
- Antagonists: Peptides: Abarelix
- Acyline
- Azaline B
- Cetrorelix
- Degarelix
- Detirelix
- Ganirelix
- Iturelix (antide)
- LXT-101
- Ornirelix (ornitide)
- Ozarelix
- Prazarelix
- Ramorelix
- Teverelix (antarelix); Non-peptides: Elagolix
- Linzagolix
- Merigolix
- Opigolix
- Relugolix
- Sufugolix
|
|---|
| Gonadotropin | | LH/hCGTooltip Luteinizing hormone/choriogonadotropin receptor | |
|---|
| FSHTooltip Follicle-stimulating hormone receptor |
- NAMs: Non-peptides: ADX-61623
|
|---|
|
|---|